Compass Pathways isn’t the first company to fashion FDA-regulated therapies out of psilocybin, but it intends to be the first one to go public.
This week, the British company is seeking to raise about $100 million at a $570 million valuation. Compass, which counts Thiel Capital among its private investors, intends to sell 6.7 million shares for between $14 and $16 each. The funds will support an ongoing Phase 2b trial intended to prove that psilocybin-based therapy can help patients with treatment-resistant depression.
About the Author Reprints
